Reta glucagon-like peptide-1 (GLP-1) receptor agonists represent a groundbreaking approach to diabetes management. These innovative drugs function by mimicking the physiological actions of GLP-1, a hormone produced by the gut in response to food. By triggering GLP-1 receptors in the pancreas, these agents increase insulin release and suppress gluca

The burgeoning landscape of emerging treatments for body management has seen the rise of both retatrutide and tirzepatide, both dual mechanism agonists targeting the GLP-1 and GIP receptors. While sharing a alike therapeutic goal – improving glycemic control and promoting significant weight loss – they exhibit intriguing variations in their pha